203 related articles for article (PubMed ID: 28609344)
1. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
West KL; Cardona DM; Su Z; Puri PK
Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
[TBL] [Abstract][Full Text] [Related]
3. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
[TBL] [Abstract][Full Text] [Related]
4. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
6. [Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans].
Xiong Y; Guo H; Zhang S; Zhang B; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):395-400. PubMed ID: 18677387
[TBL] [Abstract][Full Text] [Related]
7. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
8. CD99 expression in dermatofibrosarcoma protuberans and dermatofibroma.
Kazlouskaya V; Malhotra S; Kabigting FD; Lal K; Elston DM
Am J Dermatopathol; 2014 May; 36(5):392-6. PubMed ID: 24247571
[TBL] [Abstract][Full Text] [Related]
9. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
10. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
Kubo M; Ihn H; Yamane K; Tamaki K
Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
12. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
[TBL] [Abstract][Full Text] [Related]
13. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
Okita H; Ohtsuka T; Yamazaki S
Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
[TBL] [Abstract][Full Text] [Related]
14. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
Wick MR; Ritter JH; Lind AC; Swanson PE
Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
[TBL] [Abstract][Full Text] [Related]
15. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
16. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
17. IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Li J; Yu Y; Yang Y; Wang L; Cao J; Liang X; Xiao X; Tu Y; Chen H
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):382-5. PubMed ID: 21492256
[TBL] [Abstract][Full Text] [Related]
18. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
Goldblum JR; Tuthill RJ
Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
[TBL] [Abstract][Full Text] [Related]
19. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
Abdaljaleel MY; North JP
Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
[TBL] [Abstract][Full Text] [Related]
20. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
